Ultime notizie per Abbott Laboratories (NYSE:ABT) Azioni

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Arcblock - United States Dollar

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) (Insulet or the Company), the global leader in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54155373&amp;newsitemid=20241120268759&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=807c8b95f30f75f117e9943595c99975">tubeless insulin pump</a> technology with its Omnipod&#xAE; brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S.

News

PODD

Insulet Announces Omnipod 5 System Is Now Compatible With Abbott's FreeStyle Libre 2 Plus Sensor In The U.S.

<a href="https://abbott.mediaroom.com/press-releases?item=124678" title="https://abbott.mediaroom.com/press-releases?item=124678">https://abbott.mediaroom.com/press-releases?item=124678</a>

Biotech

General

Abbott's Amplatzer Amulet Device Demonstrates Superior Long-Term Stroke Prevention And Reduced Blood-Thinner Use In AFib Patients Compared To Watchman; Five-Year Data Presented At AHA 2024 And Published In JACC

The global plant-based Active Pharmaceutical Ingredient (API) market is projected to grow at a steady pace, reaching a valuation of $52.1 billion by 2034, according to a <a href="https://www.futuremarketinsights.com/reports/plant-based-api-market">new report</a> by Future Market Insights. The industry is expected to expand at a Compound Annual Growth Rate (CAGR) of 5.6%, fueled by rising demand for natural and sustainable pharmaceutical solutions, including <a href="https://www.benzinga.com/markets/psychedelics">psychedelics</a> and <a href="https://www.benzinga.com/topic/cannabis-products">cannabis-derived</a> compounds.
<h3 class="wp-block-heading">Rising Demand For Psychedelic And Cannabis-Based Ingredients</h3>
A significant driver of market growth is the increasing use of psychoactive and plant-derived substances in modern pharmacology. Psychedelics like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and cannabinoids such as <a href="https://www.benzinga.com/topic/cbd">CBD</a> and <a href="http://v">THC</a> are gaining attention for their <a href="http://v">therapeutic potential</a> in mental health and oncology. The U.S., a key player in the market, is leveraging biotechnological advances like <a href="https://www.genome.gov/genetics-glossary/CRISPR#:~:text=CRISPR%20(short%20for%20%E2%80%9Cclustered%20regularly,editing%20systems%20found%20in%20bacteria.">CRISPR</a> and synthetic biology to scale production of these high-demand APIs, contributing to a 4.2% CAGR.
"The global shift toward sustainable, plant-based solutions reflects both consumer interest in natural medicine and the pharmaceutical industry's focus on alternative therapies," said Sabyasachi Ghosh, associate VP at Future Market Insights. The market&#8217;s rapid expansion underscores the increasing acceptance of psychedelics and cannabis as mainstream pharmaceutical ingredients.
<h3 class="wp-block-heading">Therapeutic Applications And Key Botanical Sources</h3>
Plant-based APIs are harnessed from well-documented medicinal plants such as cannabis, ginseng, turmeric and cinchona. These natural sources contain bioactive compounds like flavonoids, terpenes and alkaloids, offering various therapeutic benefits. Major applications of plant-based APIs include pain management, anti-inflammatory treatments and oncology therapies.
The incorporation of cannabinoids, particularly CBD and THC, into pharmaceutical formulations is reshaping the landscape of pain and anxiety treatments. Similarly, psychoactive compounds from plants like Syrian rue and Psilocybe mushrooms are being explored for treating mental health disorders like depression and PTSD.
<h3 class="wp-block-heading">Regional Growth And Market Segmentation</h3>
The report highlights robust growth in Asian markets, with India leading at an 8.8% CAGR, followed closely by China (8.7%) and South Korea (8.6%). These regions are investing heavily in agricultural biotechnologies and expanding their capabilities in plant-based pharmaceutical production.
The market segments by product type, covering alkaloids, cannabinoids, <a href="https://www.benzinga.com/markets/cannabis/24/05/39064102/cannabis-terpenes-alleviate-chemo-induced-neuropathic-pain-study-shows-added-benefits-with-morph">terpenes</a>, flavonoids and polyphenols. It also includes API forms like extracts, powders and resins from botanicals such as opium poppy, turmeric, ginseng and cannabis.
<h3 class="wp-block-heading">Competitive Landscape: Psychedelics And Cannabis Companies Lead the Charge</h3>
The plant-based API sector is experiencing intense competition, particularly in the cannabis and psychedelics segments. Companies are rapidly scaling production and forming key partnerships to meet the rising demand for plant-based, pharmaceutical-grade ingredients.
Recent developments include Bright Green Corporation's agreement to supply <a href="https://www.benzinga.com/24/02/37292778/dea-clears-this-nasdaq-traded-plant-touching-firm-to-research-and-produce-schedule-i-and-ii-plant-ba">DEA-approved marijuana</a> extracts and psychedelic compounds to Benuvia Operations. Indena's authorization from Italian regulators to produce pharmaceutical-grade CBD further illustrates the expanding global footprint of cannabis-derived APIs.
Key players in the industry include the Illinois-based Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), New Mexico&#8217;s Bright Green Corporation, Indena S.p.A., headquartered in Milan, Italy, Alchem International Pvt. Ltd., based in India, Israeli Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>); Roquette Frères, based in Lestrem, France; and Sami-Sabinsa Group, based in New Jersey.
<h3 class="wp-block-heading">The Future Of Plant-Based APIs: Sustainable And Psychedelic Solutions</h3>
The growing demand for sustainable, natural treatments will likely position the plant-based API market at the forefront of global healthcare. As pharmaceutical companies continue to explore the therapeutic potential of bioactive compounds from plants, the integration of psychedelics and cannabis-derived APIs is likely to play a pivotal role in shaping the next decade of medicine.
Cover image made with AI

Cannabis

Market Summary

Psychedelics

Global

Markets

TEVA

Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids

In the last three months, 15 analysts have published ratings on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $129.93, a high estimate of $149.00, and a low estimate of $117.00. This upward trend is evident, with the current average reflecting a 4.91% increase from the previous average price target of $123.85.
<img src="https://www.benzinga.com/files/images/story/2024/1730818870_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Abbott Laboratories among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$138.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$146.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>David Lewis</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$117.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$129.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$131.00</td>
<td>-</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$119.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Abbott Laboratories. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Abbott Laboratories's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Abbott Laboratories's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>Discovering Abbott Laboratories: A Closer Look</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Financial Insights: Abbott Laboratories</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Abbott Laboratories displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 4.85%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Abbott Laboratories's net margin is impressive, surpassing industry averages. With a net margin of 15.48%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.16%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.23%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.38, Abbott Laboratories adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Ratings For Abbott Laboratories

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $143 to $149.

Price Target

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $149

Reducing Need For Repeat Procedures By 48% Compared To Balloon Angioplasty; New Data From LIFE-BTK Trial Presented At VIVA 2024
<a href="https://abbott.mediaroom.com/press-releases?item=124676" title="https://abbott.mediaroom.com/press-releases?item=124676">https://abbott.mediaroom.com/press-releases?item=124676</a>

Abbott's Esprit BTK System Shows Sustained Two-Year Benefits For Treating Severe Peripheral Artery Disease Below The Knee

WIIM

Abbott Laboratories shares are trading higher after the company announced it along with Reckitt Benckiser won its first trial in premature-infant formula litigation and is cleared of allegations of hiding bowel disease risks.

Abbott Laboratories and a unit of Reckitt Benckiser Group Plc were cleared by a jury over claims they hid risks their premature-infant formulas can cause a bowel disease that severely sickened a baby boy. It was the companies' first trial win in litigation over the products.
<a href="https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial" title="https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial">https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial</a>

RBGLY

Reported October 31: Abbott Laboratories And Reckitt Benckiser Win First Trial In Premature-Infant Formula Litigation, Cleared Of Allegations Of Hiding Bowel Disease Risks

<ul>
<li>The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failure
<ul>
<li>Trial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner in their disease progression</li>
</ul>
</li>
</ul>

Abbott Initiates First-Of-Its0Kind Clinical Trial To Improve Outcomes Patients With Advanced Heart Failure

In the current market session, Abbott Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) stock price is at $116.19, after a 0.68% decrease. However, over the past month, the company's stock increased by 2.51%, and in the past year, by 24.17%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1729618243_0.png" alt="Past Year Chart" />

<h3>Abbott Laboratories P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Abbott Laboratories has a lower P/E than the aggregate P/E of 265.82 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729618243_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Abbott Laboratories

Shares of surgical tool and medical instrument stocks are trading higher in sympathy with Intuitive Surgical, which gained on strong Q3 earnings.

On Wednesday,&nbsp;Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $10.55 billion</a>.
Organic sales growth for the underlying base business was 8.2%, led by double-digit&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41356487/abbott-laboratories-q3-earnings-revenue-and-eps-beat-company-says-well-positioned-to-achieve-upper-" rel="noreferrer noopener">growth in Medical Devices</a>. Abbott&#8217;s adjusted diluted earnings per share was $1.21, beating the analyst estimates of $1.20.
Abbott projects full-year 2024 adjusted EPS of $4.64-$4.70 versus&nbsp;<a target="_blank" href="https://www.benzinga.com/24/07/39839507/abbott-laboratories-q2-earnings-revenue-and-profit-beat-estimates-nudges-up-annual-profit-guidance-o" rel="noreferrer noopener">prior guidance of $4.61-$4.71</a> and consensus of $4.66. It forecasts fourth-quarter adjusted EPS of $1.31-$1.37 versus the consensus of $1.20.
William Blair anticipates that Abbott will return to a more typical pattern of double-digit earnings growth in the fourth quarter, a trend that is expected to continue into 2025 as the company moves past the impacts of the &#8220;COVID-cloud&#8221; management mentioned earlier.
Looking ahead to 2025, the analyst writes that Abbott has built a robust pipeline of products poised to drive a high-single-digit growth rate, an acceleration compared to pre-COVID levels.
William Blair notes that the investment landscape remains attractive, particularly given Abbott&#8217;s valuation compared to other large-cap MedTech peers experiencing similar growth.
The analyst anticipates a potential upside in EPS if macroeconomic headwinds diminish in the coming quarters, viewing 2024 as a transitional year leading to a resurgence in low-double-digit earnings growth by 2025.
Given that the stock is currently trading at 22.8 times William Blair&#8217;s 2025 EPS estimate of $5.16, the analyst maintains an <a href="https://www.benzinga.com/quote/ABT/analyst-ratings" target="_blank" rel="noreferrer noopener">Outperform rating on Abbott</a>.
<h2 class="wp-block-heading">Abbott Laboratories Stock Prediction For 2024</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Abbott Laboratories, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Abbott Laboratories, the 200-day moving average sits at $110.38, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is below the current price of $117.31. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: ABT stock is down 0.22% at $117.56 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41385280/universal-stainless-finds-new-home-as-luxembourg-based-aperam-makes-big-us-move-details" target="_blank" rel="noreferrer noopener">Universal Stainless Finds New Home As Luxembourg-Based Aperam Makes Big US Move: Details</a>.</li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Health Care

Trading Ideas

Abbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic

There are many reasons to own Abbott Laboratories (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abt#NYSE">ABT</a>), but they all boil down to one thing: consistent market-beating returns. A study published by Hendrik Bessembinder, a professor of finance at Arizona State University, found that Abbott is the 11th top-returning stock since 1937 and #1 among healthcare names.&nbsp;
The critical takeaways from the report are time and consistency: the top performers produce slower annual growth than flash-in-the-pan growth stories but do it year in and year out, compounding value over the long term. Value is driven by company growth, cash flow, and capital returns, which, in Abbott&#39;s case, include dividends and share repurchases. Abbott stock can also help reduce portfolio risk because its low beta is about 0.7x the S&amp;P 500.
<h2>High-Quality Abbott Stock: Corporate Growth That Pays You to Own It</h2>
Abbott Laboratories had a solid Q3, reporting 4.9% growth to outpace the consensus forecast despite the impact of lower COVID-related sales and discontinued business. Organically, ongoing business grew by 8.2% due to strength in the medical device segment. Medical Devices grew by 11.7% reported and 13.3% organic due to a double-digit increase in Structural Heart and Heart Failure and the release of continuous glucose monitors, showing the strength of the diversified portfolio.&nbsp;
Regarding the remaining segments, established Pharmaceuticals grew by 2.7% on a reported basis and 7% organically, offset by reported declines in Nutrition and Diagnostics. Nutrition contracted by 0.3% as reported but grew by 3.4% organically, while Diagnostics declined by 1.3% on a reported basis but grew by 1.4% organically.&nbsp;
Margin news is also solid, sustaining the outlook for balance sheet health and capital returns. The company&#39;s operating and net margin widened slightly compared to the previous year, driving earnings leverage. The operating and net operating earnings are up 12.8% and 14.6%, leaving the adjusted fully diluted EPS at $1.21 or up 6%, with margins forecasted to remain stable in Q4.&nbsp;
Abbott&#39;s guidance is favorable in that revenue targets were reaffirmed, and the mid-point for earnings was raised. The company expects full-year earnings in a range centering on $4.67 versus the $4.66 consensus, which should keep the analysts happy and support the uptrend in share prices.&nbsp;
<h2>Abbott Laboratories Capital Return Grows Safely, Drives Value for Shareholders</h2>
Abbott Laboratories&#39; capital return is safe and reliable, with a 53-year history of sustained annual increases and a low payout ratio below 50%. The balance sheet is a fortress with no red flags, leaving ample cash flow for R&amp;D, reinvestment, acquisitional cash flow, and share repurchases. Repurchase activity isn&#39;t robust but sufficient to offset dilutive forces and reduce the count annually. Highlights from Q3 include a 0.05% YTD share count reduction and a freshly amended repurchase authorization worth $7 billion or about 3.5% of the market cap before the release.&nbsp;&nbsp;
Analysts&#39; support for Abbott is strong. The trend in calendar Q3 is increasing coverage, improving sentiment, and upward price target revisions. The consensus is a Moderate Buy verging on a Strong Buy with a price target of $125, about 10% above the post-release opening price. The freshest revisions lead to the high-end range, another 10% to 15% above the consensus target, and a new all-time high when reached.
<h2>Abbott Slips Into a Buying Opportunity</h2>
The price action following the release was tepid, with share prices pulling back slightly. However, analysts and institutions support the market well, so the pullback should result in a buying signal soon. The critical support target is near $115 and will likely be tested. If the market can sustain support above that level, a move to fresh highs is likely before the year&#39;s end. If not, Abbott Laboratories&#39; share price may remain range-bound until more is available.&nbsp;
<img alt="Abbott Laboratories ABT stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241016081501_chart-abt-10162024.png" style="height:448px; width:917px" />
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/abbotts-growth-and-dividends-make-it-a-smart-portfolio-pick/">Abbott&#39;s Growth and Dividends Make It a Smart Portfolio Pick</a>&quot; first appeared on MarketBeat.

Earnings

Large Cap

Guidance

Dividends

Technicals

Abbott's Growth and Dividends Make It a Smart Portfolio Pick

Bernstein analyst Lee Hambright maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $133 to $138.

Bernstein Maintains Outperform on Abbott Laboratories, Raises Price Target to $138

UBS analyst Danielle Antalffy maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $143 to $146.

UBS Maintains Buy on Abbott Laboratories, Raises Price Target to $146

Jefferies analyst Matthew Taylor maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Hold and raises the price target from $120 to $125.

Jefferies Maintains Hold on Abbott Laboratories, Raises Price Target to $125

Mizuho analyst Anthony Petrone maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Neutral and raises the price target from $115 to $130.

Mizuho Maintains Neutral on Abbott Laboratories, Raises Price Target to $130

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported better-than-expected third-quarter <a href="https://www.benzinga.com/news/earnings/24/10/41356487/abbott-laboratories-q3-earnings-revenue-and-eps-beat-company-says-well-positioned-to-achieve-upper-">results on Wednesday.</a>
The company posted sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion. Abbott&#8217;s adjusted diluted earnings per share was $1.21, beating the analyst estimates of $1.20.
"Our results this quarter demonstrate the strength of our diversified business model," said Robert Ford, chairman and CEO of Abbott. "We're well-positioned to achieve the upper end of our initial guidance ranges for the year and have great momentum heading into next year."
Abbott projects full-year 2024 adjusted EPS of $4.64-$4.70 versus prior guidance of $4.61-$4.71 and consensus of $4.66. Abbott forecasts that in the fourth quarter of 2024, the adjusted EPS will be $1.31-$1.37 versus the consensus of $1.20.
Abbott shares gained 1.5% to close at $117.82 on Wednesday.
These analysts made changes to their price targets on Abbott following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/topic/david-lewis">Morgan Stanley analyst David Lewis</a> maintained Abbott with an Equal-Weight and raised the price target from $107 to $117.</li>
<li>Piper Sandler analyst Adam Maeder maintained the stock with an Overweight and boosted the price target from $131 to $133.</li>
</ul>
Considering buying ABT stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="512" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17091351/image-151-1024x512.png" alt="" class="wp-image-600697" style="width:668px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17091351/image-151-1024x512.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17091351/image-151-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17091351/image-151-768x384.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17091351/image-151.png 1325w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

These Analysts Increase Their Forecasts On Abbott Laboratories After Better-Than-Expected Q3 Earnings

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is doing &#8220;very, very well.&#8221; However, he added that Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) remains his favorite in <a href="https://www.benzinga.com/quote/ABBV/analyst-ratings">the group right now</a>.
AbbVie was founded in 2013 when it became a separate company from Abbott.
On Oct. 9, UBS analyst Navin Jacob maintained AbbVie with a Neutral and raised the price target from $185 to $195.
When asked about Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), he said, &#8220;I like the prospects. But you're in it for the data center, and the data center business is excellent.&#8221;
Oracle recently launched Oracle Health Clinical Data Exchange, a cloud-based solution that streamlines medical claims processing through secure, automated data exchange between <a href="https://www.benzinga.com/markets/equities/24/10/41317667/oracle-streamlines-medical-claims-processing-with-cloud-based-solution">healthcare providers and payers</a>.
Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) is a &#8220;mini-Palantir,&#8221; Cramer said. He recommended buying Palantir (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>).
On Oct. 11, B. Riley Securities analyst Lucas Pipes maintained Core Scientific with a Buy and raised the price target from $13 to $14.
&#8220;I just don't want to go there. I know that it's a good company, but I just don't want to hurt anybody,&#8221; Cramer said when asked about Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>).
The company recent said the Centers for Medicare and Medicaid Services (CMS) increased the Star rating of its PPO Medicare Advantage plans to 4 Stars for 2025, affecting payments in 2026.
GXO Logistics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>) is a &#8220;very valuable company,&#8221; the &#8220;Mad Money&#8221; host said. &#8220;Just hold on.&#8221;
GXO recently announced a new transport partnership with Matalan.
Cramer said he really likes Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>), adding that it is &#8220;terrific.&#8221;
Sweetgreen will release financial results for the third quarter after the closing bell on Thursday, Nov. 7.
Price Action:
<ul>
<li>Oracle shares gained 0.4% to settle at $174.77 on Wednesday.</li>
<li>AbbVie shares fell 0.7% to close at $190.46.</li>
<li>Core Scientific shares gained 2.2% to close at $13.25 on Wednesday.</li>
<li>GXO Logistics shares gained 2.6% to settle at $62.95.</li>
<li>Sweetgreen shares fell 0.7% to close at $37.94 on Wednesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41366043/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

ABBV

CLOV

Core Scientific, Inc. - Class A Common Stock

CORZ

ORCL

PLTR

AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham raised Clear Secure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) price target from $40 to $45. Needham analyst Joshua Reilly maintained a Buy rating. Clear Secure shares gained 5.2% to close at $37.35 on Wednesday. See how other analysts view this stock.</li>
<li>HC Wainwright &amp; Co. boosted the price target for Phunware, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) from $7 to $9. HC Wainwright &amp; Co. analyst Scott Buck maintained a Buy rating. Phunware shares climbed 17.6% to close at $6.34 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised the price target for Jack Henry &amp; Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>) from $186 to $195. Baird analyst David Koning maintained a Neutral rating. Jack Henry &amp; Associates shares gained 0.5% to close at $185.67 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised O-I Glass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) price target from $14 to $16. B of A Securities analyst George Staphos upgraded the stock from Neutral to Buy. O-I Glass shares fell 0.3% to close at $12.73 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank boosted Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) price target from $58 to $68. Deutsche Bank analyst Mark Devries maintained a Buy rating. Synchrony Financial shares gained 6.1% to close at $56.52 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) price target from $600 to $650. Mizuho analyst James Lee maintained an Outperform rating. Meta shares fell 1.6% to close at $576.79 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark raised the price target for DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) from $152 to $173. Benchmark analyst Mark Zgutowicz maintained a Buy rating. DoorDash shares gained 0.7% to settle at $149.86 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho raised Lennox International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) price target from $575 to $650. Mizuho analyst Brett Linzey maintained an Outperform rating. Lennox International shares gained 0.9% to close at $600.54 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley increased the price target for Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) from $107 to $117. Morgan Stanley analyst David Lewis maintained an Equal-Weight rating. Abbott shares rose 1.5% to close at $117.82 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Ladenburg Thalmann cut Spire Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) price target from $65.5 to $60.5. Ladenburg Thalmann analyst Paul Fremont downgraded the stock from Neutral to Sell. Spire shares closed at $65.56 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying META stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="524" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17075912/image-146-1024x524.png" alt="" class="wp-image-600449" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17075912/image-146-1024x524.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17075912/image-146-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17075912/image-146-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17075912/image-146.png 1335w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Pre-Market Outlook

DASH

JKHY

PHUN

Meta To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Thursday

First mpox case linked to African outbreak reported in U.S.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) on November 15 and set a price target of...

Wells Fargo Sticks to Its Buy Rating for Abbott Laboratories (ABT)

IXJ: Healthcare Sector Dashboard For November

How I Repurposed My Late Father's Trust Account

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President-...

Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules

The market  was quiet today but we should still expect some gains through year -end albeit a bit choppy.

What To Do After The Worst Week For Healthcare Stocks Since March 2020?

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of $133...

Wells Fargo Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Insulet's Omnipod 5 now compatible with Abbott's FreeStyle Libre 2 Plus

Optimism over global healthcare sector rises: Jefferies

Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC

ALHC

ALKS

AMGN

ANGL

APDN

BIIB

BVNKF

BVNRY

CALX

CLFD

CMRX

CODX

COLL

CPRJ

CPRO

CSCO

FRSX

GEHC

GILD

GOVX

HBAN

HNDAF

HRMY

IBHE

INVA

ISRG

JNPR

MBGAF

MBGYY

MRNA

NSANF

NSANY

RHHBF

RHHBY

RSPH

SIGA

SNYNF

STLA

TNXP

TSLA

VTRS

VWAGY

VWAPY

WOLF

Screenshot 2024-10-03 at 5.30.47 PM

DXCM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Press Releases

Abbott's Lingo™ Continuous Glucose Monitor for Health and Wellness Now Available in the U.S.

Abbott Declares 403rd Consecutive Quarterly Dividend

Abbott Hosts Conference Call for Third-Quarter Earnings

Abbott and the Big Ten Conference Tackle U.S. Blood Shortages with First-of-its-Kind, Nationwide Blood Donation Competition, 'The We Give Blood Drive'

Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping

Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range

Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure

Seamless Data: Tidepool and Abbott's New Cloud-to-Cloud Integration Partnership

New Canadian Report Shows Positivity Instead of Criticism is Key in Diabetes Management

Comments

Abbott Laboratories

Notizie

Ultime notizie per Abbott Laboratories (NYSE:ABT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO